Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. My name is Kate, and I will be your conference operator today. At this time, I would like to welcome everyone to the Amylyx Pharmaceuticals First Quarter twenty twenty six Earnings Conference Call. All participants will be in a listen only mode. After today's presentation, there will be an opportunity to ask questions. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Lindsay Allen, Vice President, Investor Relations and Communications. Please proceed. Good morning, and thank you all for joining us today to discuss our first quarter twenty twenty six financial results and business update. With me on the call today are Josh Cohen and Justin Klee, our co CEOs, doctor Camille Boudrejian, our chief medical officer, Jim Frates, our chief financial officer, and Dan Monaghan, our chief commercial officer. Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward looking statements that are based on our current beliefs, plans and expectations and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, our expectations with respect to vexatide, AMX-thirty five, AMX-one hundred fourteen, and AMX-three eighteen statements regarding regulatory and clinical developments and the impacts thereof and the expected timing thereof and statements regarding our cash runway. Actual events and results could differ materially from those expressed or implied by any forward looking statements. You are cautioned not to place any undue reliance on these forward looking statements, and AMLX disclaims any obligation to u...